A study conducted on pancreatic cancer patients with gemcitabine treatment demonstrated a correlation between CDA activity and chemoresistance and concluded that patients with 6U/mg or higher of CDA activity showed progression of disease by five-fold or more[45]. This evidence concerns the gene CDA and familial pancreatic carcinoma.